此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934 (DIALOGUE 2)

2019年9月17日 更新者:Bayer

A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Darbepoetin Alfa) in the Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment in Europe and Asia Pacific

Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood. Anaemia is common in patients with chronic kidney disease. Healthy kidneys produce a hormone called erythropoietin, which stimulates the bone marrow to produce the proper number of red blood cells needed to carry oxygen to vital organs. Chronic kidney disease is a general term that means that the kidneys are not functioning to their full potential. The study drug, BAY85-3934, is being evaluated as a drug to increase the body's ability to produce erythropoietin.

The purpose of this study is to find out if the study drug, a tablet taken orally, is safe and effective for the treatment of anaemia associated with chronic kidney disease.

The study will enroll 120 patients at multiple locations in Europe, Asia and Australia. Participation will involve a screening visit and between 12 and 15 study visits scheduled over a period of approximately 5 to 7 months. The estimated total duration of study treatment will be 16 weeks. During these scheduled visits patients will undergo a number of procedures to confirm efficacy and safety of the study drug, including measurement of heart rate and blood pressure, physical examination, Electrocardiogram and blood/urine sample collection for laboratory tests.

The study will be conducted at 3 hospitals in the UK. Bayer HealthCare AG is funding this research.

研究概览

研究类型

介入性

注册 (实际的)

126

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Ashkelon、以色列、7827804
      • Hadera、以色列、3810101
      • Kfar Saba、以色列、4428164
      • Nahariya、以色列、2210001
      • Dobrich、保加利亚、9300
      • Lovech、保加利亚、5500
      • Montana、保加利亚、3400
      • Pazardjik、保加利亚、4400
      • Sofia、保加利亚、1872
      • Stara Zagora、保加利亚、6000
      • Baja、匈牙利、6500
      • Budapest、匈牙利、1036
      • Esztergom、匈牙利、2500
      • Kaposvar、匈牙利、7400
      • Pecs、匈牙利、7624
      • Szigetvar、匈牙利、7900
    • Gyeonggido
      • Bucheon-si、Gyeonggido、大韩民国、420-767
    • Nordrhein-Westfalen
      • Bonn、Nordrhein-Westfalen、德国、53127
    • Campania
      • Napoli、Campania、意大利、80138
    • Lombardia
      • Brescia、Lombardia、意大利、25123
      • Cremona、Lombardia、意大利、26100
      • Lecco、Lombardia、意大利、23900
      • Pavia、Lombardia、意大利、27100
    • Toscana
      • Livorno、Toscana、意大利、57023
      • Chiba、日本、260-8712
      • Fukuoka、日本、810-8563
      • Nagano、日本、388-8004
    • Fukuoka
      • Kitakyushu、Fukuoka、日本、802-8555
      • Okawa、Fukuoka、日本、831-0016
    • Hokkaido
      • Muroran、Hokkaido、日本、050-0083
    • Iwate
      • Morioka、Iwate、日本、020-0066
    • Kanagawa
      • Fujisawa、Kanagawa、日本、251-8550
    • Mie
      • Kuwana、Mie、日本、511-0061
      • Grenoble Cedex 9、法国、38043
      • Pierre Benite Cedex、法国、69495
      • Bialystok、波兰、15-540
      • Radom、波兰、26-610
    • New South Wales
      • Gosford、New South Wales、澳大利亚、2250
    • Victoria
      • Reservoir、Victoria、澳大利亚、3073
      • Ankara、火鸡、06100
        • Ankara Univ. Medical Faculty
      • Ankara、火鸡、06490
        • Baskent University Medical faculty
      • Izmir、火鸡、03540
        • Sifa University Medical Faculty
      • Bucharest、罗马尼亚、010731
      • Bucharest、罗马尼亚、020475
      • Oradea、罗马尼亚、410469
      • Targu-Mures、罗马尼亚、540103
      • Liverpool、英国、L7 8XP
    • Cambridgeshire
      • Cambridge、Cambridgeshire、英国、CB2 0QQ
      • Madrid、西班牙、28007
    • Barcelona
      • L'Hospitalet de Llobregat、Barcelona、西班牙、08907
    • Madrid
      • San Sebastián de los Reyes、Madrid、西班牙、28702

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD) at screening
  • Estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m2 (Modification of Diet in Renal Disease or the formula according to Matsuo, et al.)
  • Not on dialysis and not expected to begin dialysis during the treatment period of the study (at least 16 weeks from randomization)
  • Treated with darbepoetin via intravenous (IV) or subcutaneous (SC) route with a weekly, bi-weekly, or monthly dose, having had no more than one dose change within 8 weeks prior to randomization
  • At least one kidney
  • Mean screening hemoglobin (Hb) concentration of 10.0 to 12.0 g/dL
  • Men who agree to use adequate contraception when sexually active or women without childbearing potential

Exclusion Criteria:

  • Subjects with significant acute or chronic bleeding, such as overt gastrointestinal bleeding
  • Active hemolysis or diagnosis of hemolytic syndrome
  • History of myelodysplastic syndrome, multiple myeloma, marrow fibrosis, or pure red-cell aplasia (PRCA)
  • History of hemosiderosis or hemochromatosis
  • Hereditary hemoglobinopathies (such as sickle cell disease and thalassemia major)
  • Aplastic anemia
  • Chronic lymphoproliferative diseases
  • Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy that is likely to require invasive treatment (intraocular injections or laser photocoagulation) during the study
  • Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
  • Known hypersensitivity to the study drugs (active substances or excipients of the preparations)
  • Uncontrolled and symptomatic hyperparathyroidism
  • Uncontrolled active infection
  • Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated > 3 years prior to randomization
  • Any allograft (including renal allograft) in place and on immunosuppressive therapy or a scheduled kidney transplant within the next 16 weeks (being on a waiting list does not exclude the subject)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BAY85-3934 (25mg)
Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
实验性的:BAY85-3934 (50mg)
Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
实验性的:BAY85-3934 (75mg)
Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
有源比较器:Darbepoetin alfa
Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period
大体时间:Baseline and week 12 to 16
Baseline and week 12 to 16

次要结果测量

结果测量
大体时间
Maintenance in hemoglobin target range (10.0 to 12.0 g/dL)
大体时间:Up to 16 weeks
Up to 16 weeks
Change in hemoglobin level
大体时间:Baseline up to 16 weeks
Baseline up to 16 weeks
Number of patients with hemoglobin levels outside the target range
大体时间:Week 12 to 16
Week 12 to 16
Dose level in the evaluation period
大体时间:Week 12 to 16
Week 12 to 16
Duration of exposure on each dose level
大体时间:Up to 16 weeks
Up to 16 weeks
Number of subjects requiring titration of dose
大体时间:Up to 16 weeks
Up to 16 weeks
Number of participants with serious adverse events as a measure of safety and tolerability
大体时间:Up to 16 weeks
Up to 16 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年1月28日

初级完成 (实际的)

2015年10月15日

研究完成 (实际的)

2015年11月23日

研究注册日期

首次提交

2013年12月20日

首先提交符合 QC 标准的

2013年12月20日

首次发布 (估计)

2013年12月27日

研究记录更新

最后更新发布 (实际的)

2019年9月19日

上次提交的符合 QC 标准的更新

2019年9月17日

最后验证

2019年9月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • 15261
  • 2013-001192-21 (EudraCT编号)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅